PK sample analysis

SYRINX has extensive experience of developing new methods using state-of-the-art immunological and cell based techniques for pharmacokinetic (PK) sample analysis.


Immunogenicity testing

Our laboratory employs various plate and cellbased technologies, such as TR-FIA, ECL, AlphaLISA, iLITE, TR-FRET, RIA, SPR and ELISA, to assess the immunogenicity of biological drugs and vaccines.



SYRINX offers a wide range of biomarker assays to support your drug development program.



SYRINX is offering bioanalytics of biosimilars including PK, activity, binding and immunogenicity assays to demonstrate comparability of the biosimilar products to a reference or originator drug.


GMP analytics

SYRINX provides analytical services intended for the characterization or batch release certification of sponsor’s medicinal products using variety of different analysis techniques such as ligand binding and cell based assays.


Patient monitoring

Patient monitoring services are now available!

Concentration/activity analysis and immunogenicity testing using the iLite™ technology platform.


Over 20 years of experience

In GLP bioanalytics at your service

SYRINX Bioanalytics is a Contract Research Organization (CRO) offering a large variety of modern immunoassay techniques for the bioanalysis of Biologicals, Biosimilars, Anti-drug antibodies (immunogenicity testing) and Biomarkers.

SYRINX performs bioanalytical studies in compliance with GLP/GCP and supports GMP analysis for batch release and stability studies.

We are continuously striving to fulfil the latest guideline and white paper requirements offering innovative approaches utilising our strong scientific expertise and responsive communication with the focus on quality and on time delivery.

Company overview...


SYRINX Bioanalytics is included in the OECD principles of good laboratory practice (GLP) and EU good manufacturing practice (GMP analytics) monitoring programs.



SYRINX Bioanalytics offers a wide range of state-of-the-art assay techniques ideal for the bioanalysis of biologicals/biosimilars, anti-drug antibodies, vaccines and biomarkers.



SYRINX is a member of the European Bioanalysis Forum (EBF) together with more than 50 other Pharma and CRO companies.


News and events

Upcoming events:

Past EVENTS and news:

SYRINX attended the "Biacore Analytics Workshop 2021: Innovation in emerging therapeutics and novel analytical approaches" 30 Nov 2021.

SYRINX attended the "EBF 14th Open Symposium: Science – Our Universal Language" 24-26 Nov 2021.

SYRINX will attended the "EBF Spotlight on Ligand Binding & cell-based Assays and Automation technology" 20-21 May 2021.

SYRINX attended the "EBF Training Day on managing the Practical Aspects of Immunogenicity" 23-24 Mar 2021.

SYRINX attended the "12th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals" 1-3 Mar 2021.

SYRINX attended the "EBF 13th Open Symposium: From Cyberspace - Staying Connected" 17-20 Nov 2020.

SYRINX attended the "EBF YSS: Future-proofing Bioanalysis - Contributing to a sustainable world" 24-25 Sep 2020.

SYRINX attended the "Training Day and Biomarker Focus Workshop" 15-17 Sep 2020.

SYRINX attended the "Fleming: Data Integrity in Pharma & Biotech" training 22-23 Sep 2020.

SYRINX attended the "EBF Focus Workshop: Biomarkers in Pharma R&D" 15-17 Sep 2020.

SYRINX attended the "9th Gene Quantification Event qPCR dPCR & NGS 2019" 18-22 Mar 2019.

Immunogenicity analysis - determination of cut points. We use in-house validated MS Excel-templates for statistical evaluation of cut points according to Shankar et al. (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products: J. Pharm. Biomed. Anal. 2008, 48/5: 1267-81) and Devanarayan et al. (Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points: AAPS Journal 2017, 19/5: 1487–1498). More info can be requested by sending E-mail enquiry.